TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.15M | $67.79M | n/a | −1 |
| Q2 2026 | 113 | +16 | 68.20M | $3.64B | +20 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 2.95M | n/a | $24.24M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 2.20M | n/a | $18.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.67M | n/a | $13.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | D. E. Shaw & Co. ✦ | 1.53M | n/a | $12.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 640.31K | n/a | $5.26M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Adage Capital Partners ✦ | 400.00K | n/a | $3.29M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 320.58K | n/a | $2.64M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 314.18K | n/a | $2.58M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 74.07K | n/a | $608,848 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Wellington Management ✦ | 72.66K | n/a | $597,249 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Norges Bank ✦ (passive) | 71.00K | n/a | $583,620 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 43.18K | n/a | $354,956 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 33.44K | n/a | $275,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 121.20K shares, $3,600 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 78.40K sh · $4.31M
Officer, Director · 37.27K sh · $2.02M
Officer, Director · 128.06K sh · $6.78M
Officer · 8.28K sh · $538,917
Officer, Director · 101.69K sh · $6.57M
Officer, Director · 6.80K sh · $441,795
Officer, Director · 99.72K sh · $6.31M
Officer · 79.11K sh · $5.04M
Officer · 93.60K sh · $5.92M
Officer, Director · 96.12K sh · $6.12M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology